What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence from the ICARIA-MM trial indicates that isatuximab plus pomalidomide and dexamethasone extends progression-free survival from 7.8 months to 13.3 months compared to pomalidomide plus dexamethasone, with a hazard ratio of 0.598. However, the trial is ongoing, and the data are considered immature, leading to uncertainty about long-term benefits. This strengthens the market access risk assessment and overall reimbursement probability.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for isatuximab plus pomalidomide and dexamethasone are uncertain due to limitations in clinical data. The estimates are higher than what NICE typically considers acceptable, although the treatment could be cost-effective under a managed access agreement. The committee noted the need for further data to clarify this uncertainty. This informs pricing and reimbursement risk and pharmaceutical reimbursement forecasting.
Is there quality-of-life evidence payers weigh? — Quality of life
The utility values derived from the EQ-5D-5L health questionnaire indicate a slight improvement in health-related quality of life for patients receiving isatuximab plus pomalidomide and dexamethasone compared to the comparator. The committee concluded that the utility estimates used in the economic model were appropriate, reflecting moderate improvements. These outcomes align with HTA decision predictors and support pricing and reimbursement assessment.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile of isatuximab plus pomalidomide and dexamethasone is generally favorable, with mostly mild to moderate adverse events reported. The committee noted that fewer patients discontinued treatment due to adverse events compared to the comparator, indicating good tolerability. This profile reduces payer uncertainty and supports access risk forecasting.
Was the drug compared against what payers expect? — Comparator Selection
The primary comparator, pomalidomide plus dexamethasone, is appropriate; however, the company did not consider panobinostat plus bortezomib and dexamethasone a relevant comparator due to its limited use after 3 previous lines of treatment. This raises concerns about the robustness of the evidence base. This aligns with HTA comparator analysis and strengthens the market access submission.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population is representative of patients with relapsed and refractory multiple myeloma who have had at least 3 previous lines of treatment. However, the subgroup analysis for those specifically having had 3 lines of treatment introduces some limitations due to its non-randomized nature. This enhances reimbursement likelihood rating and payer relevance.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Isatuximab plus pomalidomide and dexamethasone can be integrated into existing treatment pathways with minor adjustments. The treatment does not require new infrastructure or extensive training, making it a manageable addition to current practices. This supports budget impact analysis and facilitates market access feasibility.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of isatuximab plus pomalidomide and dexamethasone are notable, particularly given the high cost of pomalidomide. The committee expressed concerns about the overall budget impact, which may necessitate restrictions on its use. This supports pricing model stress-testing and payer evidence expectations.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
While the evidence from the ICARIA-MM trial is acceptable for decision-making, the ongoing nature of the trial and the immaturity of the data introduce significant uncertainty. The committee acknowledged the limitations in the evidence base, particularly regarding long-term outcomes. These outcomes align with HTA decision predictors and support pricing and reimbursement assessment.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There is considerable uncertainty surrounding the long-term effectiveness and cost-effectiveness of isatuximab plus pomalidomide and dexamethasone. The committee noted that the evidence base is not robust enough to confidently assess its broader impacts on the healthcare system. These factors elevate access risk forecasting within HTA evaluation frameworks.
